Bioventus (BVS) said Thursday it has divested its Advanced Rehabilitation business under its Bioness unit to private equity firm Accelmed Partners.
The deal was first announced on Oct. 1 for a total cash consideration of $45 million.
Bioventus said it gained net proceeds of about $20 million from the sale.
Shares of Bioventus were down 2.4% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments